Administration of ATXN2-ASO to the lateral ventricle after birth of the rapidly progressing murine TDP-43 ALS model resulted in a sustained, marked reduction in ATXN2 mRNA as well as prolonged survival and improved gait [120]. This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.